Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04TQT
|
||||
| Former ID |
DIB014463
|
||||
| Drug Name |
Barusiban
|
||||
| Synonyms |
FE-200440
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Androgen decline [ICD10:E20-E35] | Phase 2 | [1] | ||
| Company |
Ferring Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C40H63N9O8S
|
||||
| Canonical SMILES |
N1C(=O)[C@@H](NC(=O)[C@H](NC(=O)CCSCC[C@H](NC(=O)[C@@H]<br />(NC(=O)[C@@H]1[C@@H](CC)C)CC(=O)N)C(=O)N([C@H](CO)CCCN)<br />C)Cc1c[nH]c2c1cccc2)[C@H](CC)C
|
||||
| CAS Number |
CAS 285571-64-4
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Oxytocin receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Oxytocin signaling pathway | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| PANTHER Pathway | Oxytocin receptor mediated signaling pathway | ||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Oxytocin signaling | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00209326) A Proof of Concept Study Assessing the Effect of Four Different Single Bolus Intravenous Doses of FE200440 and Placebo on Stopping Preterm Labor. U.S. National Institutes of Health. | ||||
| REF 2 | The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.